CD274 and neoplasm: In patients with tumor-cell PD-L1 < 1%, median PFS (BICR) was comparable between NIVO + Chemo and Chemo (5.8 vs. 5.6 months; HR 0.96 [0.63–1.47]) (Online Resource 3).